ANNX实时信号 | 通过Getagraph.com最大化利润

购买 102260 min ago

@ $5.26

发出时间: 15 Feb 2024 @ 03:48

回报率: -12.65%

上一信号: Feb 14 - 22:31

上一信号: 出售

回报率: 2.24 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 04:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
今日成交量	1.87M
平均成交量	1.63M
市值	482.34M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $-0.440 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.59
ATR14	$0.0130 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock
2024-02-16	Artis Dean Richard	Buy	160 000	Stock Option (Right to Buy)

INSIDER POWER
80.78
Last 94 transactions
Buy: 9 088 380 \| Sell: 879 119

音量相关性

長: -0.47 (neutral)

短: -0.08 (neutral)

Signal:(31.536) Neutral

Annexon, Inc. 相关性

10 最正相关
RMRM	0.934
GTHX	0.93
STKL	0.913
NUTX	0.91
EYE	0.91
DXCM	0.91
SDG	0.909
EAR	0.908
SVOK	0.907
RRGB	0.906

10 最负相关
HDSN	-0.916
LCA	-0.9
MDWT	-0.896
NVCN	-0.89
SENEA	-0.885
OHAA	-0.882
HNRG	-0.879
ROKU	-0.878
IGTA	-0.877
FCBP	-0.877

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Annexon, Inc. 相关性 - 货币/商品

0.04
( neutral )

0.11
( neutral )

0.00
( neutral )

0.39
( neutral )

-0.18
( neutral )

Annexon, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-3.27M (0.00 %)
EPS:	$-1.770

Q4	2023
营收:	$0
毛利润:	$-834 000 (0.00 %)
EPS:	$-0.360

Q3	2023
营收:	$0
毛利润:	$-823 000 (0.00 %)
EPS:	$-0.430

Q2	2023
营收:	$0
毛利润:	$-810 000 (0.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.